Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
house dust mite allergen extract + CYT003-QbG10
- Development stage
- Unknown
- Lead developer
- Kuros Biosciences
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual
01
Overview
This combination comprises **house dust mite allergen extract**, an immunotherapeutic agent derived from Dermatophagoides farinae and Dermatophagoides pteronyssinus that desensitizes allergic individuals by exposing the immune system to dust mite antigens, and **CYT003-QbG10**, a synthetic **Toll-like receptor 9 (TLR9) agonist** encapsulated in virus-like particles. CYT003-QbG10 works by modulating the immune response, specifically redirecting T cell activity away from Th2 cytokine production (IL-4, IL-5, IL-13, and IgE) typical in allergies towards a more balanced Th1/Th2 profile, thereby reducing hypersensitivity symptoms. CYT003-QbG10 is developed by Cytos Biotechnology. The combination aims to improve efficacy and safety in allergen immunotherapy, with clinical studies indicating symptom reduction and improved allergen tolerance in patients with perennial house dust mite allergy[1][2][3][5][7].
- Other names
- house dust mite allergen extract
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on house dust mite allergen extract + CYT003-QbG10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on house dust mite allergen extract + CYT003-QbG10.